Pengaruh Favipiravir dan Remdesivir Pada Pasien Covid-19 dengan Komorbid Penyakit Kardiovaskular & Hipertensi Terhadap Luaran Klinis Di RSUP Fatmawati Jakarta
Keywords:
Covid-19, Demografi, Karakteristik klinik, Komorbid, Antivirus, Luaran klinis, Lama rawatAbstract
Tujuan dari penelitian ini adalah untuk menganalisis dan mengevaluasi hubungan antivirus favipiravir dan remdesivir pada pasien COVID-19 dengan komorbid penyakit kardiovaskular dan hipertensi terhadap luaran klinis di RSUP Fatmawati Jakarta. Jenis penelitian ini adalah penelitian deskriptif analitik menggunakan data retrospektif dengan desain potong lintang (cross sectional) dan pengambilan data sekunder berupa catatan rekam medis pasien periode bulan Januari-Juli 2021. Analisis hubungan antivirus pada pasien COVID-19 dengan komorbid penyakit kardiovaskular dan hipertensi terhadap luaran klinis dan lama perawatan menggunakan uji statistik Chi Square. Profil demografi pasien COVID-19 usia terbanyak adalah usia 55-64 tahun (43,3%), jenis kelamin adalah jenis kelamin perempuan (51,65%) dan derajat keparah gejala adalah ringan/sedang (75,0%). karakteristik klinik terbanyak pasien saat masuk rumah sakit mengalami batuk (72,0%), demam (63,65%). Tidak terdapat hubungan bermakna antara antivirus (favipiravir dan remdesivir) terhadap luaran klinis pada pasien COVID-19 dengan komorbid penyakit kardiovaskular dan hipertensi. Kemudian, terdapat hubungan bermakna antara antivirus (favipiravir dan remdesivir) terhadap lama rawat pada pasien COVID-19 dengan komorbid penyakit kardiovaskular dan hipertensi
References
Willyono A, Presley B, Kamallan C, Primayani D, Setiawan E, Herawati F, et al. Penyakit kardiovaskular: Seri pengobatan rasional [Internet]. Setiadi AAP, Halim SV, editors. Yogyakarta, Indonesia: Graha Ilmu; 2018 [cited 2022 Oct 18]. 204 p. Available from: http://grahailmu.id/product/penyakit-kardiovaskular-seri-pengobatan-rasional/
Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. International Journal of Infectious Diseases. 2016 Aug;49:129–33.
Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and Cardiovascular Disease. Circulation. 2020 May 19;141(20):1648–55.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061.
Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. European Heart Journal. 2021 Jan 7;42(2):206–206.
Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009 Jul;39(7):618–25.
Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449–63.
Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020;6(2):45–51.
Chinello P, Petrosillo N, Pittalis S, Biava G, Ippolito G, Nicastri E, et al. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. Schibler M, editor. PLoS Negl Trop Dis. 2017 Dec 28;11(12):e0006034.
WHO. Transmisi SARS-CoV-2: implikasi terhadap kewaspadaan pencegahan infeksi [Internet]. WHO Indonesia; 2020. Available from: https://www.who.int/docs/default-source/searo/indonesia/covid19/transmisi-sars-cov-2---implikasi-untuk-terhadap-kewaspadaan-pencegahan-infeksi---pernyataan-keilmuan.pdf?sfvrsn=1534d7df_4
Burhan E, Susanto AD, Nasution SA. Pedoman tatalaksana COVID-19 edisi 3. Jakarta: 8. Perhimpunan Dokter Paru Indonesia (PDPI); 2020. 149 p.
Al-Turjman F, editor. Artificial Intelligence and Machine Learning for COVID-19 [Internet]. Cham: Springer International Publishing; 2021 [cited 2022 Oct 29]. (Studies in Computational Intelligence; vol. 924). Available from: https://link.springer.com/10.1007/978-3-030-60188-1
Akhmerov A, Marbán E. COVID-19 and the Heart. Circulation Research. 2020 May 8;126(10):1443–55.
Damayanti H, Sajinadiyasa IGK, Risni HW, Sauriasari R. The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia. Kesmas: Jurnal Kesehatan Masyarakat Nasional. 2021 Nov 1;16(4):289–97.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020 Oct;6(10):1192–8.
Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Front Pharmacol. 2021;12:683296.
Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, et al. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. Clin Infect Dis. 2021 Dec 6;73(11):e4166–74.
Tao J, Aristotelidis R, Zanowick-Marr A, Chambers LC, McDonald J, Mylonakis EE, et al. Evaluation of the Treatment Efficacy and Safety of Remdesivir for COVID-19: a Meta-analysis. SN Compr Clin Med. 2021 Dec;3(12):2443–54.
Karya KWS, Suwidnya IM, Wijaya BS. Hubungan penyakit komorbiditas terhadap derajat klinis COVID-19. Intisari Sains Medis. 2021 Aug 31;12(2):708–17.
Willim HA, Ketaren I, Supit AI. Dampak Coronavirus Disease 2019 terhadap Sistem Kardiovaskular. e-CliniC. 2020;8(2):237–45.
Alkautsar A. Hubungan Penyakit Komorbid dengan Tingkat Keparahan Pasien COVID-19-19. Jurnal Medika Hutama. 2021 Oct 3;3(01 Oktober):1488–94.
Gunawan A, Prahasanti K, Utama MR. Pengaruh komorbid hipertensi terhadap severitas pasien coronavirus disease 2019. JURNAL IMPLEMENTA HUSADA. 2020 Aug 11;1(2):136–51.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 2020 Nov 5;383(19):1813–26.
Cai, Qingxian, dkk. 2020. Experimental Treatment with Favipiravir for COVID 19: An Open-Label Control Study. Engineering, For COVID-19: A Randomized Clinical trial.
Rahayu LAD, Admiyanti JC, Khalda YI, Ahda FR, Agistany NFF, Setiawati S, et al. Hipertensi, Diabetes Melitus, dan Obesitas Sebagai Faktor Komorbiditas Utama Terhadap Mortaitas Pasien Covid -19. J Ilmiah ahasiswa Kedokteran Indoensia. 2021;9(1)
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., Pearson, C. A. B.,Eggo, R. M. (2020). Age-dependent effects in the transmission and control of COVID-19 epidemics. Nature Medicine, 26(8), 1205–1211.
Tamaweol, D., Ali, R.H., Simanjuntak, M.L. Gambaran Foto Toraks Pada Penderita Batuk Kronis di Bagian/SMF Radiologi FK Unsrat/RSUP Prof. Dr. R. D. Kandou Manado. 2016. Jurnal e-Clinic (eCl).Vol. 4, No.1
Azer S.A. COVID-19: pathophysiology, diagnosis, complications and investigationaltherapeutics. 2020. New Microbe and New Infect (37): 1000738. Dipublikasikan 5 Agustus 2020.
Towers. P.J , “Strides develops and commences export of Favipiravir Antiviral Tablets,” vol. 532531, 2020.
Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus arbidol for COVID-19: A randomized clinical trial 2020
Perkeni. Konsensus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015.
Nafrialdi. 2012. “Antihipertensi”. Farmakologi dan Terapi Edisi 5. Jakarta: Departemen Farmakologik dan Terapeutik Fakultas Kedokteran Universitas Indonesia.
Chan, L., Chen, C.H., Hwang, J.J., Yeh, S.J., Shyu, K.G., Lin, R.T., Li, Y.H., Liu, L.Z., Li, J.Z., Shau, W.Y., Weng, T.C., 2016. Cost-effectiveness of Amlodipine Compared with Valsartan in Preventing Stroke and Myocardial Infarction Among Hypertensive Patients in Taiwan. Int J of Gen Med, Vol. 9, p. 175-182.
Ida Lisni, Devi Mujianti, Ani Anggriani. 2021. Antibiotic Profile For Covid-19 Treatment in a Hospital in Bandung”. Dalam Jurnal Ilmiah Farmako Bahari. Bandung : Fakultas Farmasi, Universitas Bhakti Kencana
Kline JM, Wietholter JP, Kline VT. Confer J pediatric antibiotic use: a focused review of fluoroquinolones and tetracyclines. US Pharm. 2012;37(8):56-59
Sharma PC, Jain A, Jain S. Fluoroquinolones antibacterials: a review on chemistry, microbiology and therapeutic prospects. Acta Pol Pharm. 2009;6(6):587 -604.
Badan POM. 2021. Monografi Azitromisin. Tanggal akses 05 agustus 2022
Cheng RZ, Kogan M, Davis D. Ascorbate as Prophylaxis and Therapy for COVID-19—Update From Shanghai and U.S. Medical Institutions. Glob Adv Heal Med. 2020;9:216495612093476
Fowler AA, Truwit, Hite HD, Morris P, DeWilde C, Priday A , Dkk. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019; 13: 1261–1270.
Murray R K, Bender D A, Botham K M, et all. Harper”s illustrated biochemistry. 28 th Ed. The McGrwaw Hill Lange : 938-940
Published
How to Cite
Issue
Section
Authors who publish with Poltekita : Jurnal Ilmu Kesehatan agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
This work is licensed under a Creative Commons Attribution-ShareAlike 2.0 Generic License.
Poltekita : Jurnal Ilmu Kesehatan is licensed under a Creative Commons Attribution-Share Alike 4.0 International License
You are free to:
- Share, copy and redistribute the material in any medium or format
- Adapt, remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
